Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Future Management of Metastatic Colorectal Cancer

September 28th 2018

Emerging Therapy in Metastatic Colorectal Cancer

September 28th 2018

BEACON Trial: Triplet Therapy in BRAF V600E

September 28th 2018

Other I-O Approaches to Metastatic Colorectal Cancer

September 28th 2018

I-O Therapy in mCRC: Ipilimumab + Nivolumab

September 28th 2018

ReDOS Trial: Optimizing Regorafenib Dosing in metastatic Colorectal Cancer

September 28th 2018

Metastatic Colorectal Cancer: Multiple Lines of Therapy

September 28th 2018

Next-Generation Sequencing and Molecular Subsets in Metastatic Colorectal Cancer

September 28th 2018

The Current Paradigm of Metastatic Colorectal Cancer

September 28th 2018

Dr. Eng Discusses the ADORE Trial in Rectal Cancer

September 19th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Published Results Confirm Regorafenib Safety, Efficacy in mCRC

September 11th 2018

Safety and efficacy findings for regorafenib in patients with previously treated metastatic colorectal cancer were consistent with previous phase III results.

Dr. McCollum on Molecular Testing in CRC

September 10th 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses molecular testing in patients with colorectal cancer (CRC).

Kopetz Highlights Emerging Regimens in Colorectal Cancer

September 7th 2018

Scott Kopetz, MD, PhD, FACP, discusses the current treatment landscape of colorectal cancer and the importance of molecular subtyping.

Dr. Becerra Discusses an Investigational Cellular Therapy in CRC

September 6th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses an investigational cellular therapy in colorectal cancer.

Bekaii-Saab Shares Insight on Regorafenib Updates in mCRC

August 29th 2018

Tanios Bekaii-Saab, MD, discusses the ReDOS and IMblaze370 trials with regorafenib trials in metastatic colorectal cancer.

Expert Discusses Finding the Optimal Treatment Strategy in CRC

August 25th 2018

A. David McCollum, MD, discusses the need for greater use of molecular profiling, the importance of tumor sidedness when selecting a treatment regimen, and the value of maintenance therapy in patients with metastatic disease.

Dr. Bekaii-Saab Discusses Regorafenib Use in mCRC

August 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).

Expert Highlights Latest Immunotherapy Efforts in CRC

August 23rd 2018

Michael J. Overman, MD, discusses the current state of immunotherapy in patients with CRC and how to optimally manage immune-related adverse events.

Dr. McCollum on Frontline Therapy for Patients With Metastatic CRC

August 21st 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).

Dr. Becerra Discusses Regorafenib Dosing in Metastatic CRC

August 20th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.